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ABSTRACT 
Primary Objective: Development of depression after TBI is linked to poorer outcomes. The 
aim of this manuscript is to review evidence for the effectiveness of current treatments.  
Research Design: Two meta-analyses were undertaken to examine the effectiveness of both 
pharmacological and non-pharmacological interventions for depression after mild –TBI 
Method and Procedures: PubMed, Medline, PsychInfo, Web of Science, and Digital 
Dissertations were searched and 13 studies located. Meta Analyst Beta 3.13 was used to 
conduct analyses of pre versus post effects then to examine treatment group versus control 
group effects.   
Main Outcomes and Results: Studies using a pre-post design produced an overall effect size 
of 1.89 (95% CI 1.20-2.58, p<.001), suggesting that treatments were effective, however the 
overall effect for controlled trials was 0.46 (95%CI -0.44-1.36, p<.001), which favoured the 
control rather than treatment groups.  
Conclusions: This study highlights the need for additional large well controlled trials of 
effective treatments for depression post-TBI. 
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INTRODUCTION 
Traumatic brain injury (TBI) is one of the most common causes of death and 
disability worldwide (Corrigan, Selassie et al. 2010). The majority (up to 90%) of TBIs are 
mild (Langlois, Keglar et al. 2003; Langlois, Rutland-Brown et al. 2006), and while most 
cases recover fully within three months (Rohling, Binder et al. 2011), a significant proportion 
report on-going difficulties. Depression is the most commonly reported psychiatric 
consequence of TBI, with reports suggesting that up to 60% of patients with TBI develop 
depression within 12 months of injury, even following a mild injury (Busch 1998; Hibbard, 
Uysal et al. 1998; Fann, Uomoto et al. 2000; Robinson and Jorge 2005; Hoge 2008). The 
etiological factors that underlie the development of depression after TBI remain unclear 
(Ownsworth 1998), although neurochemical changes and psychosocial reaction to injury have 
both been implicated (Grant 1987). There is a general consensus that a complex interaction of 
neurological, psychological and social factors contribute to the development of post-TBI 
depression (Williams and Evans 2003). 
Development of depression post-TBI has been linked to poorer post-injury outcomes, 
including increased post-concussive symptoms and cognitive deficits (Rapoport, Kiss et al. 
2006), as well as poorer psychosocial and functional outcomes (Rapoport, McCullagh et al. 
2003; Jorge, Robinson et al. 2004). Given this, treatment of depression post-TBI is clearly 
needed. 
Commonly used psychological and pharmacological treatments for major depressive 
disorder have been used to treat depression post-TBI but the effectiveness of these 
interventions is equivocal (Alderfer, Arciniegas et al. 2005; Chew and Zafonte 2009). The 
Neurobehavioural Guidelines Working Group (Warden, Gordon et al. 2006) suggest the use 
of amitriptyline, desipramine and sertraline, even though they note a lack of evidence to 
support any specific recommendations. A more recent systematic review (Fann, Hart et al. 
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2009) concluded that serotonergic antidepressants and cognitive behavioural interventions 
appeared to be the most promising interventions for depression following TBI, however they 
also noted that the studies they reviewed were difficult to compare due to study samples 
differing in TBI severity and acuity, intervention type, length of treatment and use of various 
outcome measures. In an attempt to obtain a clearer picture of the most efficacious treatment 
for depression following TBI, the current meta-analysis focuses on those with mild TBI, as 
they are the largest patient group. Studies evaluating both pharmacological and non-
pharmacological interventions were incorporated to allow direct comparisons across different 
treatment types. 
 
METHOD 
Search Criteria 
Criteria used to identify studies for inclusion in this systematic review were: (1) investigated 
a treatment intervention (pharmacological or non-pharmacological); (2) depression and/or 
depressive symptoms included as an outcome measure; (3) in an adult human population that 
included persons with mild TBI; (4) was produced after 1980; and (5) written or available in 
English. The start point of 1980 was selected in order to be consistent with the WHO 
collaborating task force on mild TBI (Carroll 2004), who provide a best-evidence synthesis of 
the literature including epidemiology, diagnosis, prognosis, treatment and economic costs. 
All study designs and types (e.g., review papers and meta-analyses) were included in the 
search, allowing studies cited in previous reviews to be identified and incorporated into the 
present study. For the purposes of this study, mild TBI was defined as Loss of consciousness 
≤ 30 minutes and/or Post traumatic amnesia < 24 hours (Traumatic Brain Injury Committee 
of the Head Injury Interdisciplinary Special Interest Group of the American Congress of 
Rehabilitation Medicine 1993). 
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Search Strategy 
Data bases searched included; PubMed, Medline, PsychInfo, and Web of Science. To 
ensure best coverage of the literature the Digital Dissertations database was also searched, as 
were the reference lists of all relevant papers, including previous reviews (Gualtien 1999; 
Comper, Bisschop et al. 2005; Fann, Hart et al. 2009), to check for any new studies that had 
not already been identified. Citations to key articles were also identified through searching 
the Web of Science and checked for any studies not already identified.  The specific search 
terms used were “depression or mood or affective or major depression or depressive 
disorder” and “brain injury or head injury or brain damage or concussion” and “mild or 
concussion or post concussive or postconcussive or minor”. A flowchart summarising study 
selection is shown in Figure 1.  
Criteria for Inclusion 
The search terms used were broad and intended to identify all papers relevant to 
depression following mild TBI in adults. Abstracts for all 292 studies identified were 
reviewed for suitability. Initially, studies focusing on children or animals were excluded. 
Studies could involve any treatment modality (i.e., pharmacological, psychological, 
educational, exercise, electroconvulsive therapy (ECT), music therapy, etc.); but were 
required to include the assessment of depression both pre- and post-treatment. In order to be 
included, studies of brain injury more broadly were required to provide separate data by TBI 
severity (i.e., data for depression in those with mild TBI). For those studies with samples not 
exclusive to TBI, results from the TBI subsample needed to be reported separately.   
In studies of “mild to moderate” TBI, the inclusion/exclusion criteria for each study 
were reviewed to determine how the groups were defined. In one such case, reported 
inclusion criteria were consistent with mild TBI (i.e., loss of consciousness ≤ 30 minutes; 
post traumatic amnesia < 24 hours)(Baker-Price 2003); and this study was therefore included. 
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In two further cases, the study authors were contacted and it was confirmed that all 
participants met these criteria (Rapoport 2005; Rapoport 2008). Where both mild and 
moderate TBI were included but separate data were not presented, study authors were 
contacted to obtain separate data for those with mild TBI (Rapoport 2008; Ashman 2009; 
Lanctot 2010; Topolovec-Vranic 2010). 
Using these criteria, abstracts were reviewed by two reviewers (SB-C and NJS). 
Discrepancies were resolved by consensus.  Studies not meeting criteria were excluded from 
further review. After reviewing the 183 abstracts in depth, 33 potential papers were obtained 
in full for more detailed review. Of these, 7 met inclusion criteria.  A further 19 of the 26 
studies that did not obviously meet criteria for inclusion had the potential to contribute data to 
the analyses and the authors were contacted (see Figure 1). A total of 13 studies were 
included in the analysis.  
Insert Figure 1 around here. 
Descriptive information of the studies included in the analyses is presented in Table 1. 
For each study, this includes the diagnostic criteria for depression, number of participants, 
timing of assessment, the outcome measure(s), the study design and type of intervention, and 
the mean and SD of the outcome measures pre and post treatment. 
Insert Table 1 around here 
Meta-analyses 
Given the studies used different outcome measures, effect sizes (Cohen’s d) were calculated 
for change from baseline scores for the treatment groups (Borenstein, Hedges et al. 2009). In 
order to calculate the effect size the standard deviations of the change scores were needed, in 
addition to the correlations between the pre and post-intervention scores. For studies where 
this information was unavailable, the standard deviations of the change scores were 
calculated from the square root of the pooled variance from the pre and post score standard 
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deviations (Borenstein, Hedges et al. 2009). For the correlations between the pre and post 
scores, we reviewed the literature to locate appropriate estimates of the correlation 
coefficients for each outcome measure, however, we were unable to find studies using a 
similar participant group within a comparable timeframe. Therefore, we followed 
recommendations from the Cochrane Handbook and used an estimated correlation of .5 
(Follman, Elliot et al. 1992; Higgins, Deeks et al. 2011). As this may not be an accurate 
estimation of the pre-post test score correlations, the overall analyses were also conducted 
using low (.3) and high (.8) correlations, which revealed no large differences between effects 
sizes, suggesting that using the an estimated correlation of .5 would not bias the results of the 
analyses. A larger positive effect size indicated a greater decrease in depressive 
symptomatology. 
The studies located for the meta-analysis used pre-post designs either with or without 
a control group. The first analyses focused on the pre-post effects, and a second analysis 
focused on studies comparing treatment and control groups. For the second analysis, 
standardised mean group differences, with a correction for overestimation (Hedges’ g) were 
used to evaluate the efficacy of the treatments (Hedges 1981). For this analysis, positive 
treatment effects were represented by a smaller (or negative) effect size and larger positive 
effect sizes favoured the control group. Meta Analyst Beta 3.13 (Wallace 2009) for windows 
was used to conduct the analyses. Overall effect sizes were estimated using random effects 
models, as there were substantial differences between the studies (e.g., diagnostic criteria, 
length of treatment it was unlikely that the studies would share a common effect size 
(Borenstein, Hedges et al. 2009).  
The I
2
 value was used as an indication of the heterogeneity of the effect sizes. This 
value reflects the proportion of the variance accounted for in the effect sizes by between 
study variance however it is not dependent on the location or spread of the true effects 
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(Borenstein, Hedges et al. 2009). I
2
 can have a value between 0-100 and it has been suggested 
that values of 25%, 50% and 75% can be considered as low, moderate or high (Higgins, 
Thompson et al. 2003). A low value suggests that the variance is due to random error, 
whereas a high I
2 
suggests that the variance is not random and may be attributable to factors 
such as treatment effect. Publication bias was assessed by inspection of funnel plots. 
Asymmetrical plots indicate the possibility of publication bias. 
 
RESULTS 
Study characteristics 
As can be seen in Table 1, we located five studies whose treatment effect was 
determined using a control group for comparison (Saran 1985; Dinan 1992; Leonard 2002; 
Lee, Kim et al. 2005; Ashman, Cantor et al. 2009), while eight studies were pre- post 
comparisons without a control group (Baker-Price and Persinger 1996; Fann, Uomoto et al. 
2001; Horsfield 2002; Baker-Price and Persinger 2003; Kanetani, Kimura et al. 2003; 
Rapoport, Chan et al. 2008; Lanctot, Rapoport et al. 2010; Topolovec-Vranic, Cullen et al. 
2010). Across the studies there was variability in how presence of depression was identified, 
however, use of Diagnostic and Statistical Manual (DSM) criteria was the most commonly 
reported (n = 7). While the modal treatment length was 6 weeks (mean = 8.15 weeks), this 
ranged from 4 weeks to 8 months. This was included as a covariate in the analyses.  
Treatments described also varied considerably, including a range of antidepressant 
medications, brain stimulation, psychotherapeutic interventions (individual, group, and 
computer mediated), and educational interventions. The most common measure of depressive 
outcomes was the Hamilton Depression Rating Scale (HAM-D), followed by the Beck 
Depression Inventory (BDI). To allow greater consistency HAM-D scores were used where 
available. 
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Pre to Post Treatment Effects 
The initial analyses focused on pre to post treatment effects. Table 2 presents the treatment 
effect, standard error, and weightings (i.e., inverse weightings according to the variance) for 
each pre to post comparison.  These are presented as a forest plot in Figure 2, along with the 
overall effect size, which is the mean effect size across the studies. For each study the effect 
size (the symbol size is proportional to study size and variance) with 95% confidence 
intervals is presented. All studies demonstrated positive effects with Cohen’s d from 0.5 to 
5.2 with an overall effect size of 1.89 (95% CI 1.20-2.58, p<.001).  
Insert Table 2 and Figure 2 around here. 
As can be seen in Figure 2, when examining the pharmacological treatments, the 
greatest positive effect was found for the selective serotonin reuptake inhibitor (SSRI) 
sertraline (Fann, Uomoto et al. 2001). Two similar sized trials of sertraline (Lee, Kim et al. 
2005; Ashman, Cantor et al. 2009) also produced much smaller but positive effects. The 
reason for the varied effects sizes is unclear as all three studies had similar inclusion criteria 
for depression, used the HAM-D as their pre and post measure, and two of the three (one 
showing a large effect and the other showing a small effect) had dosage up to 200mg/week 
(Ashman, Cantor et al. 2009) while the third had a maximum dose of 100 mg/week (Lee, 
Kim et al. 2005). Furthermore, weeks of treatment provided in the study with the high 
positive effect (7 weeks) was midway between that of the remaining studies (4 and 10 
weeks). Methylphenidate (Lee, Kim et al. 2005) was the only other pharmacological 
treatment to have an effect size greater than the pooled estimate. Citalopram (Rapoport, Chan 
et al. 2008; Lanctot, Rapoport et al. 2010), milnacipran (Kanetani, Kimura et al. 2003) and 
fluoxetine (Horsfield 2002) produced effect sizes close to the pooled estimate. Both studies 
examining amitriptyline (Saran 1985; Dinan 1992) produced effects lower than the pooled 
estimate. Within the non-pharmacological interventions, only intermittent burst-firing weak 
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magnetic field stimulation (Baker-Price and Persinger 2003) produced effects greater than the 
pooled estimate, although the confidence intervals were large. All other interventions 
produced effects sizes below the pooled estimate.  
The studies were highly heterogeneous (I
2
 = 71.1%; Tau squared = 1.20; p < .001), 
and when additional analyses were conducted, the pooled effect sizes for the pharmacological 
studies were found to be higher (d = 2.25, n = 10) than for the non-pharmacological studies (d 
= 0.97, n = 5). Another notable difference across the studies related to length of treatment, 
however a plot of effect size versus weeks of treatment revealed no significant relationship 
(slope = 0.09, p > .05). 
Figure 3 presents a funnel plot of the intervention effect estimates from individual 
studies against a measure of each study’s precision. It is typical when using funnel plots that 
the effect estimates from small studies scatter more widely at the bottom of a funnel plot, 
with the spread narrowing among larger studies. This expected distribution was not revealed 
in Figure 3, possibly as a reflection of the heterogeneity of the study interventions. Inspection 
of the funnel plot suggest that the study of sertraline, with the largest effect size (Fann, 
Uomoto et al. 2001) is an outlier as the other larger studies are more closely clustered 
together.  
Insert Figure 3 around here 
Alternatively, the plot may indicate bias, with larger studies (those with precision > 
0.6) showing greater variability in effect than would be expected. Smaller and unpublished 
studies without statistically significant effects were included (identified through inclusion in 
of the Digital Dissertations database in the search), so there are no gaps at the bottom of the 
funnel plot, suggesting that the effect calculated in a meta-analysis will not overestimate the 
intervention effect (Egger, Smith et al. 1997; Villar, Piaggio et al. 1997). 
Controlled Comparisons 
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Analyses of controlled studies were based on standardised means differences in the 
final outcome score between the control and active treatment groups (Hedges’ g). Table 3 
presents the treatment effect, standard error, confidence intervals, and weightings, for each 
treatment - control comparison. These studies are also summarised with the overall effect size 
and 95% confidence intervals in a Forest plot in Figure 4. The effect sizes ranged from –1.19 
to 2.86 with an overall effect size of 0.46 (95% CI -0.44–1.36, p <.001). As can be seen in 
Figure 4 the overall effect across studies was in favour of the control group, with only 3 
treatment-control comparisons producing effect sizes suggesting a positive effect of 
treatment. Consistent with pre-post comparisons, the findings suggest that amitriptyline is the 
least effective of the treatments trialled (Saran 1985; Dinan 1992), with mixed results for 
sertraline (Lee, Kim et al. 2005; Ashman, Cantor et al. 2009). The largest positive effect was 
found for methylphenidate (Lee, Kim et al. 2005), followed by sertraline (Lee, Kim et al. 
2005) and group format CBT (Leonard 2002). Of these only methylphenidate had confidence 
intervals which did not overlap with zero or the pooled effect. 
Insert Table 3 and Figure 4 around here 
As suggested by the lack of overlap between the confidence intervals, the studies were 
highly heterogeneous (I
2
 = 86.7%; Tau squared = 1.255; p < .001). Given the relatively small 
number of studies included in the meta-analysis it was difficult to investigate this further, 
however there was no significant relationship between treatment effect and length of 
treatment (slope =.16). 
Figure 5 presents a funnel plot of the intervention effect estimates from individual 
studies against a measure of each study’s precision.  In Figure 5, the effect estimates from 
small studies scatter more widely at the bottom of the funnel plot, with the spread narrowing 
among larger studies suggesting there is not a bias in the studies (Egger, Smith et al. 1997).  
Insert Figure 5 around here 
TREATMENT FOR DEPRESSION AFTER MILD TBI 11 
 
 
 
DISCUSSION 
These analyses were undertaken in an attempt to obtain a clearer picture of the most 
efficacious treatment for depression following mild TBI. Studies using pre-post designs and 
controlled trials evaluating both pharmacological and non-pharmacological interventions 
were incorporated to increase the number of available studies and allow direct comparisons 
across different treatment types. The overall effect size for the pre-post analysis indicated that 
depression symptoms decreased following treatment. This suggests that there may be 
effective treatments for depression post- mild TBI, with pharmacological treatments showing 
greater efficacy than other treatment approaches. In contrast, the overall effect size for the 
controlled trials (0.46) suggests that active treatment is no more beneficial than placebo. The 
only treatment showing an effect greater than zero was methylphenidate (Lee, Kim et al. 
2005), whilst treatment with amitriptyline was less effective that placebo (Saran 1985; Dinan 
1992). Other studies have indicated that methylphenidate was effective in improving attention 
post-TBI particularly processing speed and sustained attention (Chew and Zafonte 2009) 
which may mediate the improvement in depression symptoms, however its widespread use 
following TBI tends to be limited due to its potential to lower seizure thresholds.  
The effectiveness of sertraline differed across the studies included in this meta-
analysis. One study with a pre-post design (Fann, Uomoto et al. 2001) found a large positive 
effect, however the effects were less favourable in the controlled trials with one study 
suggesting that sertraline was less effective than placebo (Ashman, Cantor et al. 2009) and 
the other showed the effect to be no greater than zero (Lee, Kim et al. 2005) The most 
obvious difference between these studies is that Fann et al., (2001) used a pre-post design and 
only evaluated the effect of the placebo treatment over 1 week rather than a period equivalent 
to active treatment. Furthermore, there were differences in time since injury across the three 
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studies from approximately 1 month post- injury (Lee, Kim et al. 2005), 3-24 months post 
injury (Fann, Uomoto et al. 2001) and 17 years (on average) post-injury (Ashman, Cantor et 
al. 2009). In both controlled trials, however, the placebo group also showed a significant 
improvement over the treatment period, suggesting that the other factors (e.g., contact with 
clinic staff) rather than the active treatment may be responsible for the improvement in 
symptoms.  
In contrast to the findings of the current study, a meta-analysis examining the 
efficacy of antidepressant in treating depression in neurological disorders (including TBI, 
stroke, Parkinson’s), found that after 6-8 weeks treatment the odds of remission were twice 
that of a control group, however the authors acknowledge that there were too few studies to 
investigate the neurological disorders separately (Price, Rayner et al. 2011). This suggests 
that depression following mild TBI may require a somewhat different treatment approach. 
The non-pharmacological treatments included in the meta-analysis appeared to 
show limited efficacy in treating depression post-TBI, this is somewhat surprising as two 
earlier studies found CBT improved emotional functioning post-TBI (Tiersky, Anselmi et al. 
2005; Bradbury, Christensen et al. 2008). However, unlike the study incorporated into the 
meta-analysis, in both of these studies, the CBT was modified depending on the participants 
cognitive functioning and a diagnosis of depression was not required for inclusion in the 
study.  
Overall the findings from the current meta-analysis suggest there are limited 
effective treatments for depression after mild TBI. However, the paucity of studies examining 
the efficacy of depression treatment post mild TBI has undoubtedly affected the quality and 
robustness of the current meta-analysis. In addition to the lack of high quality trials, the 
studies included in the meta-analysis also showed a high degree of heterogeneity, which is 
largely unsurprising given the differences in inclusion criteria, depression diagnostic criteria, 
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time since injury, length of treatment and different outcome measures. Future studies 
examining treatments of depression in this population are encouraged to state clearly what 
criteria are used in defining mild TBI, and to use the HAM-D as one of their outcome 
measures in order to allow comparison to the existing literature. Though difficult to establish, 
it is suggested that some standardization of pre- to post- measurement interval established. 
The most common interval found in this review was 6 weeks, though this ranged up to 3 
months. As can be seen in Table 1, some authors conducted outcomes measurement at regular 
intervals. Thus, it is suggested that authors consider inclusion of an assessment at 6-weeks, 
even if this is in addition to other measurement time frames.  In searching the literature it was 
not surprising, given the small samples, that many authors combined TBI severity groupings. 
While small sample size may require combining these groups to determine treatment effects 
it is suggested that studies which include individuals with both mild and moderate TBI 
present their data (means and standard deviations) separately for these groups in order that 
comparisons to the literature can be made.   
 The strengths of the current study are that it is the first meta-analysis to our 
knowledge that focuses on treatment of depression after mild TBI. In addition, it highlights 
the importance of controlled trials, as focusing solely on the studies using a pre-post design 
would suggest that treatments of depression post mild TBI are effective. Addressing 
depression post-TBI is important as there is an accumulation of evidence which suggests it is 
linked to poorer outcomes across a range of areas, including cognitive, psychosocial and 
functional outcomes (Jorge, Robinson et al. 2004; Alderfer, Arciniegas et al. 2005; Rapoport, 
Kiss et al. 2006). Thus, there is a clear need for large randomised controlled trials of 
treatment for depression after mild TBI. Overall, the findings from the current meta-analysis 
support the conclusions of previous reviews, that is, there is insufficient evidence to 
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recommend a particular type of treatment for depression after mild TBI (Warden, Gordon et 
al. 2006; Chew and Zafonte 2009; Fann, Hart et al. 2009). 
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Figure 1. Overview of study review and selection. 
 
Abstracts obtained and titles 
reviewed for obvious exclusions 
(N = 292) 
Adult and human studies only  
(N = 183) 
Abstracts with treatment & 
depression as outcome  
(N = 33) 
Studies meeting all inclusion 
criteria on detailed review 
(N = 7) 
Studies not meeting all criteria 
(N = 26) 
Authors contacted for 
additional information 
(N = 19) 
Mild subgroup data 
requested 
(N = 14) 
Data for depression 
subscale requested 
(N = 4) 
7 Excluded: 
-3 mixed groups not TBI 
-1 TBI severity not measured 
-2 No intervention described 
-1 no mild TBI included 
Means and SDs 
requested for figural 
data (N = 1) 
Final Number of Included Studies   (N = 13) 
109 animal studies & paediatric 
studies removed 
 
 150 abstracts  indicate 
depression is not an outcome 
or no treatment implemented 
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Figure 2. Forest plot showing effects for pre to post treatment comparisons for each 
pharmacological and non-pharmacological treatment examined across the studies (N=226).  
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Figure 3. Funnel plot for studies included in pre- post- comparison analysis.  
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Figure 4. Forest plot showing effects (Hedges’ g) for controlled comparisons for each 
pharmacological and non-pharmacological treatment examined across the studies (N=189).  
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Figure 5. Funnel plot for studies included in controlled comparison analysis.  
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Table 1 Characteristics of the studies included in the meta-analysis. 
Reference Depression Criteria Mild TBI Number Timing of 
Assessment 
Outcome  Design and Intervention Mean (SD) Pre and Post 
Treatment by Group 
Treatment Studies with Control Groups  
Leonard, 
2002   
No depression 
inclusion criteria 
N = 40 mild TBI   
(15 GCBT, 16 
GEST, 9 Wait list 
control) 
Pre & post ; 
3 month 
follow-up 
BDI-II
 
 
Pre-post randomised  3 arm 
study: Wait-list controls, 5-
session Group Cognitive-
Behaviour therapy, 5-session 
Group Education and Support. 
GCBT pre = 16.7 (10.45) 
           post = 13.4 (8.17) 
GEST  pre = 20.5 (7.07)  
            post = 16.9 (8.02) 
Wait    pre = 18.5 (5.83)  
            post = 16.8 (6.45) 
Ashman 
et al., 
2009 
 
Major depression 
diagnosis  and 
HAM-D≥ 18 
N = 18 mild TBI    
(N = 52 total) 
Pre and post 
(pre + 10 
weeks) 
HAM-D 
BDI 
Pre post study  
Sertraline 25mg initial dose 
increasing to therapeutic level 
(max 200mg) or placebo 
Sertraline  pre = 32.5 (1.73) 
                 post = 21.0 (10.23) 
Placebo pre = 27.1 (7.60) 
                 post = 12.1 (6.49) 
Lee et al., 
2005  
 
DSM-IV criteria  
Major Depressive 
episode 
 
N = 30 mild TBI  
 
(10 each 
Methylphenidate, 
Sertraline & placebo)
 
Pre & post 
(pre + 4 
weeks). 
HAM-D 
BDI 
Double-blind pre- post parallel 
groups. 
Methylphenidate 5mg/day 
increased until 20 mg/day. 
Sertraline 25mg/day increased 
until 100mg/day 
Methylphenidate 
        pre = 25.2 (4.1) 
          post = 15.7 (5.6) 
Sertraline   pre = 27.6 (6.2) 
           post = 20.0 (4.6) 
Placebo    pre = 25.7 (4.7) 
          post = 22.3 (4.2) 
Saran, 
1985  
DSM-III Major 
Depression. 
Feighner (1972) 
criteria  
N = 10 mild TBI     
N = 12 controls 
Pre & post 
(pre + 4 
weeks) 
HAM-D 
 
Pre post study.  
Amytriptyline 100mg/day which 
could be raised 25 mg/day every 
2-3 days to maximum 
300mg/day. 
mTBI      pre = 34.0  
               post = 24.0 
Control   pre = 34.0 
               post = 10.0 
Dinan, 
1992  
DSM-III Major 
depression  
HAM-D > 17 
N = 13 mild TBI     
N = 13 matched 
functionally 
depressed controls.  
Pre and post 
(pre + 1, 3, 4, 
and 6 
weeks). 
LSSAD 
HAM-D 
Single blind matched control 
study. Amitriptyline 100 
mg/daily, inc by 50mg/week to 
max 250 mg/day. 
mTBI    pre = 25.0 (7.2) 
             post = 18.8 (6.8) 
Control  pre  = 24.0 (~7.5) 
              post = 10.0 (3.0) 
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Pre- Post- Comparisons without Control Groups  
Topolovec-
Vranic et 
al., 2010  
Score  ≥12 on the 
PHQ-9 
N = 9 mild.             
(N = 21 total)  
Pre & post 
(pre + 6 
weeks) & 12-
month 
follow-up 
CES-D 
PHQ-9 
Pre-post study. 
MoodGYM- a free interactive 
internet based program. 
Weekly for 6 weeks 
pre = 31.78 (11.42) 
post = 22.0 (9.43) 
Baker-Price 
& 
Persinger, 
1996  
Persistent or 
frequent 
intermittent  
depression. Non-
responder to 
medications. 
N = 4
 b
 
 
Pre and post 
(pre + 1, 2, 3, 
4, and 5 
weeks). 
BDI 
SCL-90R 
WPSC  
Pre-post study 
Burst-fire magnetic field every 3 
sec for 30 minutes weekly in 
temporoparietal areas for 5 
weeks. 
Weekly BDI scores: 
1 = 33 (9);    
2 = 27 (7);  
3 = 20 (10);  
4 = 21 (8);  
5 = 17 (9) 
Baker-
Price, 2003   
Chronic 
depression post-
TBI not 
responding to 
antidepressants 
N = 14
 b  
mild-
moderate but  meet 
criteria for mild. 
Pre & post 
(pre + 6 
weeks) and 
6-week 
follow-up 
BDI Pre-post design with 2 areas of 
brain treated. 
Burst-fire magnetic field once 
every 3 sec for 30 minutes once 
per week for in temporal or 
frontal areas for 6 weeks 
pre = 19.7 (8.6) 
post = 14.1 (5.2) 
follow-up = 15.1 (7.6) 
(Area of treatment not related to 
size of effect) 
Fann et al., 
2001  
 
DSM-III-R Major 
Depression   
HAM-D score 
>17 
N = 15 mild TBI 
 
Baseline, 
and at 1, 2, 4, 
6, and 8 
weeks after 
Sertraline 
introduced. 
HAM-D Single-blind non-randomised. 
“Pre” measure taken then 1 week 
Placebo, then Sertraline 25mg (1 
week); 25-50mg/day (week 2); 
25-100 mg/day (week 3). 25-200 
mg/day (weeks 4-8) dependent on 
tolerance/response.  
pre = 25.0 (4.36) (pre placebo) 
post = 7.2 (5.30) 
Kanetani et 
al., 2003  
DSM-IV Major 
depressive episode 
or minor 
depression  
N = 7 (GCS > 13) at 
time of injury. (10 in 
total) 
Pre, 2, 4, and 
6 weeks 
HAM-D Open pre-post study. 
Milnacipran 30 mg/day twice 
daily, dose adjusted weekly to 
max dose range 30-150 mg. 
pre = 31.83 (13.82) 
post= 14.17 (12.99) 
Horsfield, 
2002  
Either “no or 
moderate 
depression”. 
N = 5 males with 
head injury (some 
with multiple, all 
Pre & post 
(pre +8 
months) 
HAM-D Open label pre-post study. 
Fluoxetine 20-60 mg/day for 8 
months 
pre = 18. 0 (7.07) 
post = 9.8 (8.07) 
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Criteria not 
specified. 
LOC < 2 hrs) 
Rapoport et 
al., 2008  
Major Depression 
(SCID-IV) 
N = 33 mild TBI Pre and Post 
(pre + 6 or 
10 weeks) 
HAM-D Citalopram 20 mg/day initial dose 
to max 50 mg/day; 6 or 10 weeks 
pre = 24.27 (6.15) 
post = 15.93 (8.35) 
follow-up = 12.63 (7.52) 
Lanctot et 
al., 2010 
DSM-IV (SCID) N=44 mild TBI 
(N=90  total) 
Pre and Post 
(pre+ 6 
weeks) 
HAM-D Pre-post study 
Citalopram 20 mg/day; 6 weeks 
pre = 24.05 (5.96) 
post = 16.64 (8.36) 
BDI= Beck Depression Inventory; CES-D= Center for epidemiological studies-Depression Scale; HAM-D = Hamilton Depression Rating Scale; LSSAD = Leeds Scale for 
the Self-assessment of Anxiety and Depression; TBI = Traumatic brain injury;  PHQ-9= Patient health questionnaire-9 item depression module; SCL-90R= Symptom 
Checklist 90-revised; WPSC=Wahler Physical Symptoms Checklist   
b
 While this group is described as mild-moderate by the authors, their inclusion criteria (unconsciousness <20 minutes, memory loss < 24 hours) would fall within accepted 
definitions for mild TBI.  Bold text indicates time frame of data used in analysis and outcome  measure used for analyses. 
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Table 2. Treatment effect (Cohen’s d), standard error (SE), confidence intervals and 
weightings for each pre- to post- comparison.  
 
Study Name Treatment 
Effect 
SE 95% Confidence Interval Weight Treatment 
  Lower Upper  
Leonard (2002) 0.50 0.79 -1.04 2.04 0.051 Group CBT 
Leonard (2002) 0.68 0.69 -0.67 2.03 0.066 Group Education 
Topolovec-Vranic (2010) 1.33 1.08 -0.78 3.44 0.027 MoodGym 
Baker-Price (1996) 2.51 1.50 -0.43 5.45 0.014 Magnetic Field  
Baker-Price (2003) 1.15 0.70 -0.22 2.52 0.064 Magnetic Field 
Fann (2001) 5.21 0.57 4.10 6.32 0.098 Sertraline 
Ashman (2009) 2.72 0.58 1.59 3.85 0.094 Sertraline 
Lee (2005) 1.99 0.73 0.55 3.43 0.058 Sertraline 
Lee (2005) 2.77 0.70 1.41 4.13 0.065 Methylphenidate 
Dinan (1992) 1.25 0.74 -0.19 2.69 0.058 Amitriptyline 
Saran (1985) 1.13 1.12 -1.06 3.32 0.025 Amitriptyline 
Kanetani (2003) 1.86 1.16 -0.41 4.13 0.023 Milnacipran 
Horsfield (2002) 1.53 1.23 -0.88 3.94 0.021 Fluoxetine 
Rapoport (2008) 1.63 0.47 0.71 2.55 0.143 Citalopram 
Lanctot (2010) 1.46 0.40 0.67 2.25 0.192 Citalopram 
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Table 3. Treatment effect (Hedges’ g), standard error, confidence intervals, and weightings, 
for each treatment - control comparison.  
 
 
Study  Treatment Effect SE 95% Confidence Interval Weight Treatment 
Lower Upper 
Leonard (2002) -0.43 0.43 -1.26 0.41 0.15 Group CBT 
Leonard (2002) 0.02 0.42 -0.80 0.84 0.15 Group Education 
Ashman (2009) 1.10 0.31 0.49 1.71 0.27 Sertraline 
Lee (2005) -0.50 0.46 -1.39 0.39 0.13 Sertraline 
Lee (2005)  -1.19 0.49 -2.16 -0.23 0.11 Methylphenidate  
Dinan  (1992) 1.59 0.46 0.69 2.49 0.13 Amitriptyline 
Saran (1985) 2.86 0.64 1.60 4.11 0.07 Amitriptyline  
CBT= cognitive behaviour therapy  
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